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Introduction: The microangiopathic hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome is a rare
and potentially fatal complication of pregnancy. Here, to the best of our knowledge, we describe only the second
reported case of this syndrome in a woman with cystic fibrosis.
Case presentation: This report describes the case of a 26-year-old woman of Caucasian ethnicity with mild cystic
fibrosis bronchiectasis who ultimately manifested the triad of microangiopathic hemolysis, elevated liver enzymes,
and low platelet count in the third trimester of pregnancy. Her baby was delivered successfully after a semi-elective
caesarean section.
Conclusions: Pregnancies in patients with cystic fibrosis are associated with an increased rate of complications. This
case is of importance as it describes only for the second time the successful delivery of a baby in a women with
cystic fibrosis, in a pregnancy also threatened by the microangiopathic hemolysis, elevated liver enzymes, and low
platelet syndrome. This case will be of special interest to obstetricians, pediatricians, and medical, nursing and allied
health staff involved in the delivery of cystic fibrosis care.Introduction
‘Hemolysis, Elevated Liver enzymes, and Low Platelet
count’ (HELLP) syndrome is a rare complication of preg-
nancy. It usually occurs in the setting of severe pre-
eclampsia and manifests almost exclusively after the 20th
week of gestation, with up to 30% of cases occurring in the
immediate post-partum period [1]. It can be life-
threatening to both mother and baby, and definitive treat-
ment is delivery of the baby, which usually results in reso-
lution [2]. Here, we describe only the second reported case
of a young woman with mild cystic fibrosis (CF)-related
lung disease who presented in the third trimester of her
second pregnancy with HELLP syndrome [3].
Case presentation
A 26-year-old Caucasian woman who had mild lung dis-
ease presented to our facility. Her pre-partum forced* Correspondence: james.geake@southernhealth.org.au
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reproduction in any medium, provided the orexpiratory volume in one second (FEV) was 2.62 L (87%
predicted). Her pre-partum body mass index (BMI) was
24. She was chronically infected with Pseudomonas
aeruginosa. In addition, she was pancreatically insuffi-
cient and had CF-related diabetes treated with insulin.
Her glycemic control was acceptable with a hemoglobin
A1C (HbA1C) level of 6.1%. She did not have microal-
buminuria as estimated by a spot albumin:creatinine
ratio. Eight years previously she had delivered a healthy
child via a normal vaginal delivery after spontaneous
rupture of membranes at 36 weeks’ gestation. The preg-
nancy had been uncomplicated.
Her second pregnancy was unplanned and she had con-
ceived with a new partner. Following confirmation of the
pregnancy, she was referred to a high-risk pregnancy
clinic where she was reviewed regularly by a multidiscip-
linary team supervised by an obstetrician, a respiratory
physician and an endocrinologist. The first two trimesters
proceeded without significant medical complication. Dur-
ing the 26th week of pregnancy, a routine out-patient re-
view revealed a fall in her lung function (FEV1 2.13 L,
approximately 71% predicted) accompanied by increasedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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slightly elevated at 118/87. A hospital admission for treat-
ment of her fall in lung function was declined and she was
given a two-week course of oral ciprofloxacin at a dose of
750 mg twice a day. This was tolerated poorly due to nausea.
Two weeks later, in the 28th week of pregnancy, she
developed worsening nausea and further exacerbation of
her respiratory symptoms with some accompanying left
upper quadrant discomfort. Her blood pressure was 123/
90. The results of a urinary test strip screening for protein-
uria were negative. A hospital admission was again
declined and treatment with oral ciprofloxacin for a pre-
sumed mild pulmonary exacerbation was continued, and
she was prescribed oral metoclopramide, with outpatient
follow up arranged in one week. She was advised to present
to hospital sooner in the event of clinical deterioration.
Our patient re-presented one week later with increasing
nausea and a persistent impairment of lung function
(FEV1 2.09; 69% predicted). She was admitted to hospital.
At this time, her blood pressure was 153/89. Laboratory
investigation results revealed hemoglobin of 12.3 g/dL,
platelet count of 101× 109 cells/ml (normal range 150 to
400× 109 cells/ml), serum alanine transaminase (ALT) of
179 mmol/L (normal range <65 mmol/L), lactate dehydro-
genase (LDH) of 279 mmol/L (normal range <240 mmol/L)
and urate of 523 mmol/L (normal range 150 to
400 mmol/L). There was no significant proteinuria as
assessed by a urinary protein/creatinine ratio and this
remained unchanged throughout the admission. Similarly,
serial assessment of her coagulation and renal function
failed to reveal any abnormality. On admission, a fetal
ultrasound was within normal limits.
A diagnosis of pre-eclampsia with some features of
HELLP syndrome was made, in the setting of a respiratory
exacerbation. In addition to her regular medications, she
was put on intravenous aztreonam at a dose of 2 g every
six hours. She was given two 11.4 mg doses of intramuscu-
lar betamethasone at 12-hour intervals to assist with fetal
lung maturation. Aminoglycosides were not given to avoid
any potential harm to the fetal kidneys. Over the next five
days she remained hypertensive with a systolic blood pres-
sure ranging from 150 to 190 mmHg, but her platelet
count increased to 239× 109 cells/ml and the results of
liver function tests (LFTs) progressively normalized. How-
ever, on the fifth day there was a precipitous drop in plate-
let count to 62× 109 cells/ml and an increase in ALT to
118 mmol/L, accompanied by a fall in hemoglobin to
8.8 g/dL with red cell fragments observed on blood films
taken at this time. A diagnosis of HELLP syndrome was
made and a semi-elective caesarean section was performed
10 hours later under spinal anesthesia. HELLP-specific
treatment, in particular magnesium sulfate was not admi-
nistered. A healthy baby girl was delivered. Her APGAR
scores were 9 and 9 at one and five minutes, respectively.All of our patient’s blood parameters normalized the day
following birth of her child. Our patient recovered without
further medical complication. Four years later, our patient’s
lung function remains stable, although she continues to
have intermittent exacerbations of her bronchiectasis. Our
patient’s child has reached normal age-specific milestones.
Discussion
HELLP syndrome complicates approximately one to two
in every 1000 pregnancies. Many consider it a severe vari-
ant of the pre-eclamptic spectrum, although this is contro-
versial as at times it occurs without other pathological
hallmarks of the disease, as occurred in this case with the
absence of proteinuria. Although the pathophysiology of
pre-eclampsia is yet to be fully defined, broadly it is
thought to arise as a consequence of deficient placenta-
tion, followed by the liberation of vasoactive mediators
and subsequent maternal endothelial dysfunction [4]. Risk
factors for the development of HELLP syndrome are: mul-
tiparity, age over 25 years, Caucasian ethnicity, and a his-
tory of poor pregnancy outcome [5]. The definitive
treatment for both pre-eclampsia and HELLP syndrome is
delivery of the baby, and there is broad consensus that this
should be expedited if the pregnancy is at or beyond
34 weeks of gestation and especially if assessments of fetal
status are not reassuring, or if there is significant maternal
disease as in this case. While the presence of cystic fibrosis
and HELLP syndrome may not have been of direct rele-
vance to each other in this case, the diagnosis of HELLP
syndrome was somewhat obscured. Individuals with CF
frequently develop abnormal LFTs when unwell or
dehydrated because of biliary sludging and she appeared
to be making a recovery before acutely deteriorating, at
which point the diagnosis became clear.
With respect to CF lung disease and pregnancy, small case
series have not documented adverse maternal outcomes for
patients with relatively preserved lung function (FEV1
> 60%), although rates of prematurity would appear to be
increased [6]. It is unlikely that the manifestation of HELLP
syndrome adversely impacted on our patient’s lung function.
However, although the outcome was favorable in the case of
our patient, our patient’s CF added complexity to acute man-
agement as her lung function had deteriorated and people
with CF are more at risk during general anesthetic proce-
dures, especially if a peri-operative inability to clear airway
secretions is compounded by post-operative abdominal pain.
The major differential diagnoses to consider in this case
were thrombotic thrombocytopenic purpura and the
hemolytic uremic syndrome. However, the presence of
hypertension prior to the development of severe microan-
giopathic hemolysis and platelet destruction, as well as the
absence of any associated renal dysfunction, plus the rapid
resolution of clinical and biochemical derangements upon
delivery of the baby argues against these other diagnoses.
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To the best of our knowledge this is only the second
reported case of HELLP syndrome manifesting in a preg-
nant individual with CF. The case highlights the importance
of delivery of the baby as the definitive management route
for the disorder. As survival in CF increases and an increas-
ing number of women are becoming mothers, there needs
to be a low threshold of suspicion when patients develop a
slight worsening of their LFTs in the setting of an elevated
BP and the findings in our case caution against attributing
some of the biochemical manifestations of HELLP syn-
drome simply to the underlying CF. Furthermore it demon-
strates the importance of managing CF pregnancies
through multidisciplinary high-risk antenatal clinics.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Respiratory and Sleep Medicine, Monash Medical Centre, 246
Clayton Road, Clayton 3168, Australia. 2Department of Respiratory Medicine,
Hobart 7001Tasmania, Australia. 3Department of Allergy, Immunology and
Respiratory Medicine, Alfred Hospital, Commercial Road, Prahan, Melbourne
3181, Australia. 4Adult Cystic Fibrosis Centre, The Prince Charles Hospital,
Rode Road, Chermside, Queensland 4032, Australia. 5Tasmanian Adult Cystic
Fibrosis Unit, Hobart 7001Tasmania, Australia.
Authors’ contributions
JG, ED, and DR reviewed the case and completed the case summary. JG and
DR reviewed the literature and completed the case discussion. All authors
read an approved the final manuscript.
Received: 24 September 2011 Accepted: 22 March 2012
Published: 23 May 2012
References
1. Sibai BM, Ramadan MK, Usta L, Salama M, Mercer BM, Friedman SA:
Maternal morbidity and mortality in 442 pregnancies with HELLP
syndrome. Am J Obstet Gynecol 1993, 169(Suppl 4):1000–1006.
2. Sibai BM: Diagnosis, controversies, and management of the HELLP
syndrome. Obstet Gynecol 2004, 103:981–991.
3. Patel K, Bhugra P, McCormack M, Dudney T: A 22 year old pregnant cystic
fibrosis female and HELLP syndrome. Am J Respir Crit Care Med 2010,
181:A5898.
4. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP:
Pathophysiology of hypertension during preeclampsia: linking placental
ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol
2007, 294:H541–H550.
5. Padden MO: HELLP Syndrome: recognition and perinatal management.
Am Fam Physician 1999, 60(Suppl 3):829–836.
6. McMullen AH, Pasta DJ, Frederick PD, Konstan MW, Morgan WJ, Schechter
MS, Wagener JS: Impact of pregnancy on women with cystic fibrosis.
Chest 2006, 129(Suppl 3):706–711.
doi:10.1186/1752-1947-6-134
Cite this article as: Geake et al.: Hemolysis, elevated liver enzymes, and
low platelet (HELLP) syndrome in a 26-year-old woman with cystic
fibrosis: a case report. Journal of Medical Case Reports 2012 6:134.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
